SLC22A5 and colorectal carcinoma: Accordingly, luteolin-mediated activity could potentiate the sensitivity of CRC cells to chemotherapeutic agents such as oxaliplatin, as OCTN2 is a determinant factor in oxaliplatin uptake [60].